Clinical Trials

Refractory or Recurrent Solid Tumor

NCT06726421 2026-01-15

STROKER

Phase 3 Recruiting

252 enrolled

Carcinoma, Renal Cell, Kidney Neoplasms

NCT02029001 2025-08-07

MOST plus

900 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT05679921 2025-07-16

Pazopanib With or Without Pembrolizumab for Metastatic Soft Tissue Sarcoma

116 enrolled

NCT02331498 2025-05-20

PAZOGLIO

Phase 1/2 Recruiting

51 enrolled

CNS

Glioblastoma

NCT03660930 2025-04-30

Nab-Sirolimus and Pazopanib Hydrochloride in Treating Patients With Advanced Nonadipocytic Soft Tissue Sarcomas

Phase 1/2 Terminated

19 enrolled 26 charts

NCT06895733 2025-03-26

Study of Pazopanib Combined With Palbociclib for Refractory Solid Tumors With Co-amplified in the 11q13(FGF3/4/19/CCND1)

Phase 1/2 Recruiting

65 enrolled

Solid Tumor, Adult

NCT01543763 2025-03-21

Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors

Phase 1 Completed

90 enrolled

Neoplasm Metastasis, Sarcoma, Disease Progression

NCT01767636 2025-03-03

Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer

38 enrolled 12 charts

Oncocytoma, renal, Carcinoma, Renal Cell

NCT06816771 2025-02-10

Evaluation of the Efficacy and Safety of Pazopanib in Combination with TGI/CIV for Recurrent or Refractory Rhabdomyosarcoma in Children or Adolescents

38 enrolled

Recurrence, Rhabdomyosarcoma

NCT06739395 2024-12-18

Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion

300 enrolled

Phase 2 Active not recruiting

Solid Tumor

NCT02203760 2024-11-15

PazoDoble

58 enrolled

Carcinosarcoma, Leiomyosarcoma, Recurrence

NCT02207309 2024-08-09

Pazopanib Maintenance Phase II

1 enrolled 4 charts

BreastGenitourinaryGynecologicHead & Neck

NCT05949424 2023-11-29

OPTI-DOSE

Phase 4 Unknown

30 enrolled

Breast Neoplasms, Carcinoma, Renal Cell, Ovarian Neoplasms, Thyroid Neoplasms, Endometrial Neoplasms

NCT00827372 2023-10-16

A Study of Vascular Endothelial Growth Factor (VEGF) Inhibition in Patients With Unilateral Upper Extremity Lymphedema Following Treatment for Cancer

10 enrolled 10 charts

Lymphedema

NCT02383251 2023-09-06

TAPAZ

118 enrolled

Gynecologic

Ovarian Neoplasms

NCT04741438 2023-08-30

Advanced Cancers

NCT05816642 2023-04-18

Application Circulating Tumor DNA Dynamic Monitoring in Clinical Treatment of Metastatic Renal Cell Carcinoma

Phase NA Unknown

500 enrolled

Carcinoma, Renal Cell

NCT02066285 2023-03-27

Trial of Pazopanib in Patients With Solitary Fibrous Tumor and Extraskeletal Myxoid Chondrosarcoma

96 enrolled

BreastOther solid neoplasm

Chondrosarcoma, Extraskeletal Myxoid, Neoplasm Metastasis, Solitary Fibrous Tumors

NCT01407562 2022-09-28

Study of Pazopanib, Paclitaxel, and Carboplatin in Patients With Advanced Solid Tumors

Phase 1 Terminated

34 enrolled

Unspecified Adult Solid Tumor - Protocol Specific

NCT01462630 2022-08-19

Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma

29 enrolled 10 charts

Hemangiosarcoma, Sarcoma

NCT02303028 2022-06-28

TOPAZ

Phase 1/2 Completed

30 enrolled

Solid Tumors

NCT02450136 2022-06-15

Single-arm Study to Evaluate the Safety and Efficacy of Pazopanib, in Subjects With FGFR2 Amplification, FGFR2 Mutation Refractory Solid Tumors

Phase NA Completed

2 enrolled

Refractory Solid Tumors

NCT02691767 2022-06-15

Study to Evaluate the Safety and Efficacy of Pazopanib, in Subject With Refractory Solid Tumors

Phase NA Completed

2 enrolled

Refractory Solid Tumors

NCT01498458 2022-06-10

PazoX

Phase 1 Completed

9 enrolled 15 charts

Breast

Breast Neoplasms

NCT01157091 2022-06-08

Pazopanib Hydrochloride in Treating Patients With Stage IV Kidney Cancer

28 enrolled 10 charts

Carcinoma, Renal Cell

NCT02357810 2022-06-07

Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas

178 enrolled 16 charts

Liposarcoma, Sarcoma, Osteosarcoma

NCT03334409 2022-03-31

Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed by Surgery

5 enrolled 16 charts

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT02212015 2022-03-22

EVA

26 enrolled 16 charts

Hemangiosarcoma

NCT01035658 2021-10-28

Pazopanib/Doxil in Adv Relapsed Plat Sensitive or Resistant Ovarian, Fallopian or Primary Peritoneal Adenocarcinoma

Phase 1/2 Terminated

22 enrolled 12 charts

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01532687 2021-09-27

Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma

54 enrolled 12 charts

Chondrosarcoma, Extraskeletal Myxoid, Fibrosarcoma, Hemangiosarcoma, Leiomyosarcoma, Liposarcoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Synovial, Sarcoma, Alveolar Soft Part, Neurofibrosarcoma, Hemangioendothelioma, Epithelioid, Histiocytoma, Malignant Fibrous, Desmoplastic Small Round Cell Tumor

NCT01392183 2021-09-20

Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)

69 enrolled 15 charts

Pathologic Complete Response, Carcinoma, Renal Cell, Kidney Neoplasms, Neoplasm Metastasis

NCT01548144 2021-09-13

Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer

Phase 1 Terminated

178 enrolled

Advanced Cancers

NCT02959554 2021-09-08

NIVOSWITCH

49 enrolled

Carcinoma, Renal Cell, Neoplasm Metastasis

NCT01465659 2021-08-05

Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery

Phase 1/2 Completed

29 enrolled 16 charts

Carcinoma, Islet Cell

NCT02055690 2021-05-17

PAZOFOS

Phase 1/2 Terminated

21 enrolled

Gynecologic

Ovarian Neoplasms

NCT01743482 2021-05-14

Pazotest-01

43 enrolled

Neoplasms, Germ Cell and Embryonal, Testicular Neoplasms

NCT02960906 2021-04-26

BIONIKK

200 enrolled

Clear-cell metastatic renal cell carcinoma

NCT01636908 2021-04-15

ICK

Phase NA Completed

43 enrolled

Tumor-Agnostic

Neoplasms

NCT01361334 2021-04-08

PAZOPANIB-AML